Aernoud Fiolet

115 The LoDoCo2 trial rationale, design, and baseline characteristics 58. T.Misawa,M. Takahama, T. Kozaki, et al.Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol, 14 (5) (2013), pp. 454-460 59. F. Martinon, V. Pétrilli, A. Mayor, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440 (7081) (2006), pp. 237-241 60. J.N. Fordham, J. Kirwan, J. Cason, et al. Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann Rheum Dis, 40 (6) (1981), pp. 605-608 61. E. Apostolidou, P. Skendros, K. Kambas, et al. Neutrophil extracellular traps regulate IL-1 β - mediated inflammation in familial Mediterranean fever. Ann Rheum Dis, 75 (1) (2016), pp. 269- 277 62. N.C. Raju, Q. Yi, M. Nidorf, et al. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: A pilot randomized controlled trial. J Thromb Thrombolysis, 33 (1) (2012), pp. 88-94 63. ClinicalTrials.gov. COACS colchicine for acute coronary syndromes; NCT01906749. 2013. https://clinicaltrials.gov/ct2/show/NCT01906749. Accessed August 15, 2019. 64. ClinicalTrials.gov. Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke (CONVINCE). NCT02898610. https://clinicaltrials.gov/ct2/show/NCT02898610. Published 2016. Accessed August 15, 2019.